anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Mental health and wellness influence patients with hip pain and dysfunction secondary to Femoroacetabular Impingement Syndrome, acetabular dysplasia, and labral injury. Disorders of mental wellness may impact hip preservation surgery patients both before and after surgery. Major depression and generalized anxiety are the two most common diagnoses that affect hip preservation surgery patients. There are dozens of unique questionnaires that can subjectively and objectively characterize the mental health of patients with hip pain. Pain threshold and pain tolerance are two issues that must be recognized to optimally predict treatment outcome in an informed consent shared decision-making discussion. Patient expectations may also significantly influence preoperative symptoms and postoperative outcome. Pain threshold, pain tolerance, and patient expectations are entities traditionally viewed as qualitative and unmeasurable. However, many valid and reliable methods exist to quantitatively assess these patient-specific variables. Recent original research and synthetic review publications have consistently concluded similar findings: patients with disorders of mental wellness generally have lower preoperative patient-reported outcome scores, do improve following surgery, albeit to a lesser magnitude than non-mental disorder patients, and ultimately have lower postoperative scores at their final follow. As with most orthopaedic surgery literature, the investigation of mental health and hip preservation is primarily via retrospective level four evidence with small numbers of patients from a single centre and single surgeon at short-term follow-up. Although hip preservation surgeons are orthopaedic surgeons by training and practice, they must be able to recognize mental wellness disorders and either treat or refer when suspected or identified.
OBJECTIVE: The aim of this study is to investigate the effects of sarilumab on unacceptable pain [UP; visual analogue scale (VAS) >40 mm] and inflammation in patients with moderately-to-severely active rheumatoid arthritis.
METHODS: In this post hoc analysis of the KAKEHASI study, 243 patients received methotrexate with sarilumab 150 or 200 mg or placebo every other week, over 52 weeks. The proportion of patients with UP and correlations of changes in pain VAS from baseline with uncontrolled inflammation (C-reactive protein ≥1 mg/dl) and disease activity indices were assessed.
RESULTS: Almost 80% of patients (192/243) had UP at baseline, including ∼60% of patients with uncontrolled inflammation. Among patients receiving sarilumab, inflammation decreased rapidly, with 90% of patients achieving controlled inflammation by Week 2, while 63.1% continued to have UP. The proportion of patients with UP further decreased by Week 16 (28.5%, sarilumab vs. 64.0%, placebo). By Week 52, only ∼10% of patients had UP. Changes in pain VAS correlated with most disease activity indices and patient-reported outcomes. However, marked correlations between changes in pain VAS and C-reactive protein were observed only at Week 16.
CONCLUSION: Sarilumab treatment reduced UP and inflammation in Japanese patients with rheumatoid arthritis.
The present invention relates to a traditional Chinese medicine which is characterized in that the traditional Chinese medicine is composed of 10 to 50 weight percentages of red sage roots, 5 to 50 weight percentages of yam, 5 to 45 weight percentages of hemlock parsley and 5 to 45 weight percentages of pueraria roots. The present invention has the preparation which comprises the following steps: step 1, the red sage roots, the yam, the hemlock parsley and the pueraria roots are respectively weighed; step 2, the red sage roots and the pueraria roots are extracted by water under the temperature from 20 to 80 DEG C to be filtrated, and filtrated liquid A is obtained; step 3, the yam and the hemlock parsley are decocted and extracted by water to be filtrated, and filtrated liquid B is obtained. The filtered liquid B and the filtered liquid A are merged to pass through a large porous adsorption resin column, and the merged liquid is washed by water until the Molish reaction is negative. The merged liquid is washed by ethanol or aqueous ethanol until the effluent liquid is colorless. Eluent is collected, and the ethanol is separated out, concentrated, dried and pulverized. The traditional Chinese medicine can be used for preparing the medicine used for treating cardiac and cerebral vascular diseases. The traditional Chinese medicine of the present invention has the advantages of obvious medical effect, few toxic and side effects, convenient administration, stable and reliable quality, and excellent clinic popularizing and operating value.
Pain is an unpleasant sensation, ranging from slight discomfort to intense suffering. However, since a great extent of pain is a subjective phenomenon, it has frequently defied objective, quantitative measurement. Traditionally, physicians have had to assess a patient's pain by relying on the patient's own description. Self-description is not only subjective by definition; it is often inaccurate, in part because it is difficult for subjects to precisely articulate their pain while in the midst of a pain experience. Moreover, the report might be impossible when the subject cannot communicate

Presently, in order to quantify pain, the care provider asks the patient to rate his/her pain intensity using one-dimensional scale usually scored from 0 to 10. This scale is known as Numeric Pain Scale. This and other measures are used by the care providers to estimate the correct treatment dose and or to track a treatment progress. Due to its impact on care provider decision to prescribe painkiller mediation, some patients also intentionally misrepresent the existence or extent of their pain. Yet, without any reliable basis for denying such prescriptions, physicians generally must assume that the claims are truthful, even when they may suspect a lack of sincerity. Otherwise, the care provider may be accused of inhumane treatment. Conversely, other patients may underreport their pain, again for a variety of reasons.

The presented clinical trial is intended to implement, validate performances and evaluate efficacy of the pain monitoring device for automated assessment of patient's pain level. During the trial, up to 100 healthy young adults will be voluntarily inflicted by pain stimuli. The pain stimuli will be thermal heat pain stimulus and cold water pain stimulus applied with different intensities. Plurality of Non-Invasive Physiological Measurements will be recorded from volunteers and their Numeric Pain Scale reports will be monitored before, during and after the pain induction. Additional information such as age, gender, ethnicity, etc. will be collected as well. The collected database will be used to implement the algorithm that applies modern signal processing and machine learning methods in order to differentiate between different pain levels. The algorithm will be later integrated into pain monitoring device. The efficacy of the algorithm of the pain monitor will be tested by comparing its results to the patient pain reports towards a given pain stimuli.
Zmax is indicated for the treatment with mild to moderate infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below. [See CLINICAL STUDIES (14)]

Acute bacterial sinusitis in adults due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae.

Community-acquired pneumonia in adults and pediatric patients six months of age or older due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae, in patients appropriate for oral therapy. Pediatric use in this indication is based on extrapolation of adult efficacy. [See USE IN SPECIFIC POPULATIONS (8.4)]

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Zmax and other antibacterial drugs, Zmax should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to Zmax. [See Clinical Pharmacology (12.4)] Therapy with Zmax may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly.
Aims: There is increasing evidence that volume-targeted ventilation (VTV) holds benefits for preterm infants in comparison to pressure-limited ventilation. It is not known whether the same is true in the case of infants born at term. This study aims to compare pressure-limited to VTV in term-born infants.

Hypothesis: Volume-targeted will be associated with significantly earlier extubation compared to pressure-limited ventilation Primary outcome: Time to extubation. Methods: Ventilated infants 34 weeks or more gestational age at birth were recruited and randomly allocated to receive either pressure-limited or VTV. Adjustments to ventilator settings were made according to the trial protocol. Infants were deemed to have met failure criteria if they required HFOV or peak pressures of more than 30 cm of water. Analysis will be by intention-to-treat.
PROBLEM TO BE SOLVED: To obtain the subject preparation capable of improving the percutaneous absorbability of vidarabine and manifesting excellent handleability and feeling of use by formulating the vidarabine which is an antiviral agent in a specific cream base. SOLUTION: This cream agent is obtained by including vidarabine as an active ingredient and consists essentially of 0.05-5 wt.% of the vidarabine, 3-20 wt.% of a higher alcohol (e.g. cetostearyl alcohol or octyldodecanol), 3-15 wt.% of a humectant (e.g. glycerol or propylene glycol), 3-20 wt.% of fatty acid esters (e.g. diisopropyl adipate or isopropyl myristate), 0.1-15 wt.% of an emulsifying agent (e.g. a glycerol ester of a fatty acid or a sorbitan ester of a fatty acid) and water. Thereby, the resultant cream agent has ultrahigh clinical effects due to excellent releasability and percutaneous absorbability of the drug and is capable of manifesting sufficient effects even in a small amount, excellent in feeling of use, or the like, and effective in treating herpes zoster, herpes labialis, or the like.
INTRODUCTION: Urinary incontinence is a major public health problem. Although, as a condition, it is well documented in the literature, there is little information on its social representations. The study of its representations could make it possible to improve the way it is handled and the treatment suffers receive.
PURPOSE OF THE RESEARCH: The aim of this study was to understand the representations of the general French population on the subject of urinary incontinence.
METHODS: This involved carrying out a declarative quantitative study using questionnaires. To do this, 1803 people were surveyed all over France. First, a descriptive statistical analysis was carried out using the participants' socio-demographic data. Second, a logistic regression-type association was made between the dependent and independent variables.
RESULTS: Urinary incontinence elicits a certain level of disgust in the general population. Still a taboo subject, it seems to be of little interest to some members of the population. The condition is also often poorly understood, especially by men, the younger generations, and the inhabitants of urban areas in western France.
CONCLUSIONS: This quantitative study helped shed key light on the French population's perceptions of urinary incontinence and the methods of prevention available. It also helped determine the participant profiles associated with these representations. Going forward, it seems worthwhile to focus on informing and educating these populations on the subject.
Nervousness and insomnia are the most common adverse reactions but are usually controlled by reducing dosage and omitting the drug in the afternoon or evening. Other reactions include hypersensitivity (including skin rash, urticaria, fever, arthralgia, exfoliative dermatitis, erythema multiforme with histopathological findings of necrotizing vasculitis, and thrombocytopenic purpura); anorexia; nausea; dizziness; palpitations; headache; dyskinesia; drowsiness; blood pressure and pulse changes, both up and down; tachycardia; angina; cardiac arrhythmia; abdominal pain; weight loss during prolonged therapy; libido changes; and rhabdomyolysis. There have been rare reports of Tourette’s syndrome. Toxic psychosis has been reported. Although a definite causal relationship has not been established, the following have been reported in patients taking this drug: instances of abnormal liver function, ranging from transaminase elevation to severe hepatic injury; isolated cases of cerebral arteritis and/or occlusion; leukopenia and/or anemia; transient depressed mood; a few instances of scalp hair loss; serotonin syndrome in combination with serotonergic drugs. Very rare reports of neuroleptic malignant syndrome (NMS) have been received, and, in most of these, patients were concurrently receiving therapies associated with NMS. In a single report, a ten year old boy who had been taking methylphenidate for approximately 18 months experienced an NMS-like event within 45 minutes of ingesting his first dose of venlafaxine. It is uncertain whether this case represented a drug-drug interaction, a response to either drug alone, or some other cause.

In children, loss of appetite, abdominal pain, weight loss during prolonged therapy, insomnia, and tachycardia may occur more frequently; however, any of the other adverse reactions listed above may also occur.
Block copolymers comprise a core block formed of hydrophilic monomers and have pendant zwitterionic groups, and at least two terminal blocks, comprising stimulus-responsive groups. The core block has a degree of polymerisation of at least 100, whilst the terminal blocks have an average degree of polymerisation of at least 20. A solution of polymer in a liquid may be caused to change its characteristics, for instance rheology, upon being subjected to a stimulus such as a change in temperature or pH. Examples comprise core blocks formed of 2-methacryloyloxyethyl-2'-trimethylammonium ethylphosphate inner salt (MPC) and terminal blocks formed of 2-(diisopropylamino)ethyl methacrylate. Upon changing the pH from around 2 to around 8, an aqueous solution of the block copolymer gels, the solution becoming mobile again upon lowering the pH. The effect is due to deprotonation of a quaternary ammonium pendant ion to form a non-ionised group and subsequent protonation to form an ionised group. This changes the hydrophilicity of the terminal blocks and allowing formation of a network of micellar structures when the pendant groups are not ionised and relatively hydrophobic and associated in micelles.
Species from Candida parapsilosis complex are frequently found in neonatal candidemia. The antifungal agents to treat this infection are limited and the occurrence of low in vitro susceptibility to echinocandins such as micafungin has been observed. In this context, the chaperone Hsp90 could be a target to reduce resistance. Thus, the objective of this research was to identify isolates from the C. parapsilosis complex and verify the action of Hsp90 inhibitors associated with micafungin. The fungal identification was based on genetic sequencing and mass spectrometry. Minimal inhibitory concentrations were determined by broth microdilution method according to Clinical Laboratory and Standards Institute. The evaluation of the interaction between micafungin with Hsp90 inhibitors was realized using the checkerboard methodology. According to the polyphasic taxonomy, C. parapsilosis sensu stricto was the most frequently identified, followed by C. orthopsilosis and C. metapsilosis, and one isolate of Lodderomyces elongisporus was identified by genetic sequencing. The Hsp90 inhibitor geladanamycin associated with micafungin showed a synergic effect in 31.25% of the isolates, a better result was observed with radicicol, which shows synergic effect in 56.25% tested yeasts. The results obtained demonstrate that blocking Hsp90 could be effective to reduce antifungal resistance to echinocandins.
This study primarily aims at comparing the sensitivity and specificity of overnight 5HIAA value, 24-hour 5HIAA value and plasma 5HIAA value, in patients with small-intestine neuroendocrine tumors. Secondary objectives include the correlation of 5HIAA values with chromogranin A, carcinoid syndrome and tumor burden and the evaluation of the compliance to the diet and its correlation with 5HIAA values.

The study group will include patients with proven neuroendocrine tumors of various stages and functioning syndrome profile. A control group will be constituted with subjects having irritable bowel syndrome, in which a neuroendocrine tumor is ruled out. After providing informed consent, patients fitting with inclusion criteria will be included in the study. Patients will have to follow a specific diet, and interrupt/avoid certain medication, during the 2 days before and the 2 days during the sampling period. Whole urine samples will be collected during 2 consecutive days, in 4 parts (day1, night 1, day 2, night 2). Blood samples will be collected at the morning of days 2 and 3. Observance with diet and drug restriction will be evaluated at the morning of day 3.
Patients receive irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes once every 2 weeks. Patients also receive yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A IV over 25 minutes once in weeks 3 and 9.Treatment continues in the absence of disease progression or unacceptable toxicity.
NEW MATERIAL:An antibody specifically bonding with neutrophile and produced from a hybridoma of a myeloma cell and a cell producing an antibody against a protein antigen having a molecular weight of 33,000 Dalton (by SDS- polyacrylamide gel electrophoresis). USE:Useful as a reagent for accurately determining neutrophile in biospecimen to diagnose immunoinsufficiency diseases, proliferative or exudative inflammatory diseases, etc. When the antibody is bonded to a remedy for the above diseases, the drug becomes reactive exclusively with neutrophile to improve the remedying effect and prevent side effect. PREPARATION:For example, neutrophile obtained from human by Ficoll technique is used as a raw material to produce a protein having a molecular weight of 33,000 Dalton. Spleen is aseptically extracted from an animal immunized with said protein to obtain a spleen cell as an antibody-producing cell. The antibody-producing cell is fused with a myeloma cell and the obtained hybridoma is monoclonized by conventional process.
The invention relates to the medicine, in particular to the production of the drugs and may be used in chemical-and-pharmaceutical industry for manufacturing the tablets of the cardiovascular drug containing Nitroglycerin. The method comprises mixing the active substance with the excipient followed by the wet granulation of the mixture. The wet granulate is dried, coated by the powder, caked, and subjected to the dry granulation. Finally, the tablets are compressed. According to the invention, the diluted Nitroglycerin is mixed with the peppermint oil. The mixture is then mixed in two stages with the prepared excipient representing the mixture of lactose and starch. Prior to the wet granulation, the mix is moistened with the starch paste.
The invention belongs to the technical field of new application and new indications of medicines, and discloses a medicine for adjusting intestinal microbial disorder of heart failure and application thereof. In addition, ferulic acid has been applied to clinical auxiliary diagnosis and treatment of ischemic cardiovascular and cerebrovascular diseases, and is recorded by Chinese pharmacopoeia, and on the basis of the ferulic acid, a new application of ferulic acid in treatment of heart failure intestinal flora disorder is expected to be realized. The invention provides a method for delaying the process of heart failure by adding lactobacillus, which is beneficial to improving the cardiac function of patients with heart failure. The mortality rate of the heart failure is high, and the delay of the rapid progress of the heart failure has important clinical significance in improving the life quality and the survival rate of patients. The ferulic acid is safe and reliable. Based on the invention, ferulic acid is expected to be used for adjusting the disturbance of the heart failure intestinal flora and improving new indications of heart functions.
The present invention relates to recombinant protein of hypoglycemic peptide and human lysozyme and its use. The hypoglycemic peptide in the fusion protein is GLP-1 or its analog and has amino acid sequence of one of those shown in SEQ ID Nos. 1-5; and the human lysozyme has amino acid sequence as shown in SEQ ID No. 6. The hypoglycemic peptide and the human lysozyme are connected in one of the following four connection modes: hypoglycemic peptide-connecting peptide-human lysozyme, hypoglycemic peptide-human lysozyme, human lysozyme-connecting peptide-hypoglycemic peptide and human lysozyme-hypoglycemic peptide. The fusion protein has the hypoglycemic activity of GLP-1 maintained, prolonged half life, as well as anti-infective activity and AGE level-lowering function of human lysozyme, and may be used in preparing medicine for treating diabetes and diabetes complication.
A glass-ceramic containing Li2O, CaO, Al2O3, SiO2, platinum and Nb2O5 is disclosed. It is highly suitable for use in dental restorations because of its combination of castability, chemical durability and mechanical strength. The aesthetic qualities of natural teeth may be reproduced by proper control of processing parameters, e.g. addition of coloring additives and devitrification heat treatment schedule. Dental restorations may be made by casting a melt in a conventional dental laboratory investment mold, followed by devitrification. Fracture of cast margins is avoided because of the mechanical strength and toughness of the glass-ceramic. Partial restorations can be bonded with dental cement directly to the tooth of a recipient without the need for building the restoration upon an undercoat of metal alloy.
Zoledronate therapy \& PET scan ;2 scans \[about 1-2 weeks apart\] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility, Bone scan (within 4 weeks prior to registration), bone turnover markers, and PSA will be obtained pretherapy. After that, Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration.